Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 2
Submit an article Journal homepage
130
Views
4
CrossRef citations to date
0
Altmetric
Review

Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer

Hind T Hatoum Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA. [email protected]
,
E David Crawford University of Colorado, Denver, Mail Stop #F710, PO Box 6510, Aurora, CO 80045, USA
,
Sandy Kildegaard Nielsen European Market Access Ferring International Center SA, Chemin de la Vergognausaz 50, CH-1162 St. Prex, Switzerland
,
Swu-Jane Lin Adjunct Faculty, Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, 833 South Wood St., Chicago, IL 60612, USA
&
Dennis C Marshall Medical Affairs, Ferring Pharmaceuticals, Inc. 4 Gatehall Drive, Parsippany, NJ 07054, USA
Pages 251-259 | Published online: 09 Jan 2014

References

  • Yan B, Noone AM, Yee C, Banerjee M, Schwartz K, Simon MS. Racial differences in colorectal cancer survival in the Detroit metropolitan area. Cancer 115(16), 3791–3800 (2009).
  • Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9(Suppl. 1), S3–S8 (2007).
  • Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J. Natl Compr. Canc. Netw. 8(2), 211–223 (2010).
  • Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 75(3), 642–647 (2010).
  • Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59(4), 572–583 (2011).
  • Pommerville PJ, de Boer JG. GnRH antagonists in the treatment of advanced prostate cancer. Can. J. Urol. 17(2), 5063–5070 (2010).
  • Tombal B, Miller K, Boccon-Gibod L et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57(5), 836–842 (2010).
  • Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 108(6), 806–813 (2011).
  • Konski A. Cost–effectiveness of intensity-modulated radiation therapy. Expert Rev. Pharmacoecon. Outcomes Res. 5(2), 137–140 (2005).
  • Purmonen TT. Cost–effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 383–393 (2011).
  • Iskedjian M, Hemels M, Iscoe N, Fleshner N, Einarson T. Cost–effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer. Value Health 5(3), 197 (2002).
  • Hemels M, Iskedjian M, Iscoe N, Fleshner N, Einarson T. Cost–utility analysis of LHRH agonists in the treatment of metastatic prostate cancer. Value Health 5(3), 129 (2002).
  • Bayoumi AM, Brown AD, Garber AM. Cost–effectiveness of androgen suppression therapies in advanced prostate cancer. J. Natl Cancer Inst. 92(21), 1731–1739 (2000).
  • Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 45(4), 633–640 (1995).
  • Konski A, Sherman E, Krahn M et al. Economic analysis of a Phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86–10). Int. J. Radiat. Oncol. Biol. Phys. 63(3), 788–794 (2005).
  • Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost–effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J. Urol. 174(2), 547–552; discussion 552 (2005).
  • Konski A, Watkins-Bruner D, Brereton H, Feigenberg S, Hanks G. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 106(1), 51–57 (2006).
  • Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology 66(4), 835–839 (2005).
  • Iannazzo S, Pradelli L, Carsi M, Perachino M. Cost–effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value Health 14(1), 80–89 (2011).
  • Lu L, Peters J, Roome C, Stein K. Cost–effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 109(8), 1183–1192 (2012).
  • Fisher D, Brereton NJ, Nielsen SK, Tate E. A cost utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in Scotland. Presented at: ISPOR 14th Annual European Congress. Madrid, Spain, 5–8 November 2011.
  • Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost–effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 11(3), 233–248 (2002).
  • Samant RS, Dunscombe PB, Roberts GH. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol. Oncol. 21(3), 171–177 (2003).
  • Grosse SD. Assessing cost–effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoecon. Outcomes Res. 8(2), 165–178 (2008).
  • Weinstein MC, O’Brien B, Hornberger J et al.; ISPOR Task Force on Good Research Practices–Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 6(1), 9–17 (2003).
  • Patrick DL, Burke LB, Powers JH et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl. 2), S125–S137 (2007).
  • Watkins JB. Creating models that meet decision makers’ needs: a US payer perspective. Value Health 15(6), 792–793 (2012).
  • Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health 13(5), 613–623 (2010).
  • Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994–2004. Med. Decis. Making 28(5), 713–722 (2008).
  • Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost–effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302(13), 1437–1443 (2009).
  • Williams I, Bryan S, McIver S. How should cost–effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J. Health Serv. Res. Policy 12(2), 73–79 (2007).
  • Drummond MF, Mason AR. European perspective on the costs and cost–effectiveness of cancer therapies. J. Clin. Oncol. 25(2), 191–195 (2007).
  • Mason A, Drummond M, Ramsey S, Campbell J, Raisch D. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J. Clin. Oncol. 28(20), 3234–3238 (2010).
  • Drummond M, Weatherly H. Implementing the findings of health technology assessments. If the CAT got out of the bag, can the TAIL wag the dog? Int. J. Technol. Assess. Health Care 16(1), 1–12 (2000).
  • Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet 362(9391), 1225–1230 (2003).
  • Claxton K, Neumann PJ, Araki S, Weinstein MC. Bayesian value-of-information analysis. An application to a policy model of Alzheimer’s disease. Int. J. Technol. Assess. Health Care 17(1), 38–55 (2001).
  • Claxton K, Sculpher M, Culyer A et al. Discounting and cost–effectiveness in NICE – stepping back to sort out a confusion. Health Econ. 15(1), 1–4 (2006).
  • Hoomans T, Ament AJHA, Evers SMAA, Severens JL. Worthwhile implementation of evidence-based guidelines into clinical practice: how to determine the investment potential for guideline implementation and value for money of implementation strategies? Presented at: The International Health Economics Association 6th World Congress. Copenhagen, Denmark, 8–11 July 2007.
  • Hoomans T, Fenwick EA, Palmer S, Claxton K. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value Health 12(2), 315–324 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.